Get started
Author

Gregg A. Timony

Observed names: G A Timony, G Timony, G. Timony, G.A. Timony, Gregg A Timony, Gregg Timony
OpenAlex ID: A5113650310
Ozanimod (RPC1063) is a potent sphingosine‐1‐phosphate receptor‐1 (S1P 1 ) and receptor‐5 (S1P 5 ) agonist with autoimmune disease‐modifying activity
2016 · F L Scott, B Clemons, et al. · British Journal of Pharmacology · 310
PDF
Rationally Designed High-Affinity 2-Amino-6-halopurine Heat Shock Protein 90 Inhibitors That Exhibit Potent Antitumor Activity
2007 · Srinivas R. Kasibhatla, Kevin Hong, et al. · Journal of Medicinal Chemistry · 126
7‘-Substituted Benzothiazolothio- and Pyridinothiazolothio-Purines as Potent Heat Shock Protein 90 Inhibitors
2006 · Lin Zhang, Junhua Fan, et al. · Journal of Medicinal Chemistry · 116
Results From the First‐in‐Human Study With Ozanimod, a Novel, Selective Sphingosine‐1‐Phosphate Receptor Modulator
2017 · Jonathan Q. Tran, Jeffrey P. Hartung, et al. · The Journal of Clinical Pharmacology · 113
PDF
Synthesis and Biological Evaluation of a New Class of Geldanamycin Derivatives as Potent Inhibitors of Hsp90
2004 · Jean-Yves Le Brazidec, Adeela Kamal, et al. · Journal of Medicinal Chemistry · 84
Inhibition of mast cell degranulation by novel small molecule MRGPRX2 antagonists
2024 · Joshua Wollam, Michelle Solomon, et al. · Journal of Allergy and Clinical Immunology · 78
PDF
Orally Active Purine-Based Inhibitors of the Heat Shock Protein 90
2005 · Marco A. Biamonte, Jiandong Shi, et al. · Journal of Medicinal Chemistry · 73
Antiproliferatiye effects of recombinant human bone morphogenetic protein-2 on human tumor colony-forming units
1998 · Hiroshi Soda, Eric Raymond, et al. · Anti-Cancer Drugs · 65
Cardiac Safety of Ozanimod, a Novel Sphingosine‐1‐Phosphate Receptor Modulator: Results of a Thorough QT/QTc Study
2017 · Jonathan Q. Tran, Jeffrey P. Hartung, et al. · Clinical Pharmacology in Drug Development · 63
PDF
Pharmacokinetics, Pharmacodynamics, Allometry, and Dose Selection of rPSGL-Ig for Phase I Trial
2000 · Soo Peang Khor, Kyle McCarthy, et al. · Journal of Pharmacology and Experimental Therapeutics · 53
Protein engineering of novel plasminogen activators with increased thrombolytic potency in rabbits relative to activase
1991 · G.R. Larsen, G.A. Timony, et al. · Journal of Biological Chemistry · 42
Site-directed mutagenesis in human tissue-plasminogen activator. Distinguishing sites in the amino-terminal region required for full fibrinolytic activity and rapid clearance from the circulation.
1990 · T J Ahern, G E Morris, et al. · Journal of Biological Chemistry · 34
Dimeric ansamycins—A new class of antitumor Hsp90 modulators with prolonged inhibitory activity
2006 · Hong Zhang, Yong‐Ching Yang, et al. · International Journal of Cancer · 19
Replacement of finger and growth factor domains of tissue plasminogen activator with plasminogen kringle 1. Biochemical and pharmacological characterization of a novel chimera containing a high affinity fibrin-binding domain linked to a heterologous protein
1991 · P R Langer-Safer, T J Ahern, et al. · Journal of Biological Chemistry · 13
MRGPRX2 Antagonist EP262 Potently Inhibits Agonist-Induced Mast Cell Degranulation In Vitro and In Vivo
2023 · Joshua Wollam, Michelle Solomon, et al. · Journal of Allergy and Clinical Immunology · 6
Pharmacokinetics and Pharmacodynamics of RPC1063 and Its Metabolites in Healthy Adult Volunteers (P1.211)
2014 · Gregg Timony, Jennifer Brooks, et al. · Neurology · 5
Safety and Tolerability of Orally Administered RPC1063, a Novel S1P1 Receptor Modulator, in Healthy Adult Volunteers, Results of a Phase 1 Study (P01.178)
2013 · Allan Olson, Jeffrey Hartung, et al. · Neurology · 5
Metabolites of RPC1063 Contribute to In Vivo Efficacy (P05.157)
2013 · Fiona Scott, Gregg Timony, et al. · Neurology · 5
P356 Safety and PK results of a thorough QT/QTc (TQT) study of orally administered RPC1063, a novel, selective S1P1 receptor agonist
2014 · A. Olson, J. Hartung, et al. · Journal of Crohn s and Colitis · 4
The Disposition of Quinine in the Rat Isolated Perfused Liver: Effect of Dose Size
1990 · M D Coleman, G Timony, et al. · Journal of Pharmacy and Pharmacology · 4
Sa1221 Rpc1063, a Potent, Selective S1P1 Receptor Modulator, Is Active in a Therapeutic IBD Model and Exhibits Favorable PK/PD Properties in Healthy Volunteers
2013 · Jennifer Brooks, Robert J. Peach, et al. · Gastroenterology · 3
Sa1222 Results of a Safety and Tolerability Study of Rpc1063, a Novel Orally Administered Sphingosine-1-Phosphate Receptor 1 (S1p1r) Agonist, in Healthy Adult Volunteers
2013 · Allan Olson, Gregg Timony, et al. · Gastroenterology · 2
Absence Of A Relevant Effect On Cardiac Repolarization In A QT/QTc (TQT) Study of RPC1063, A Novel, Selective S1P1 Receptor Agonist, In Healthy Adult Volunteers (P2.229)
2014 · Jeffrey Hartung, Allan Olson, et al. · Neurology · 1
The Preclinical Safety Profile of RPC1063, a Selective and Potent Sphingosine 1-Phosphate 1 Receptor (S1P1R) Agonist (P01.158)
2013 · Gregg Timony, Jennifer Brooks, et al. · Neurology · 1
358 A Small Molecule S1P1 Receptor Agonist With Significant Efficacy in Animal Models of Inflammatory Bowel Disease (IBD)
2012 · Bryan Clemons, Harry Dedman, et al. · Gastroenterology · 1
Works count: 27
Citation count: 1,228
H-index: 13
I10-index: 14
Year
Topic
Type